SLCO2A1 encodes Solute Carrier Organic Anion Transporter Family Member 2A1 (also known as OATP2A1 or PGT), a proton-coupled organic anion transporter that mediates the cellular uptake of prostaglandins and other organic anions. Expressed throughout the body including the brain, SLCO2A1 plays critical roles in prostaglandin homeostasis, inflammation regulation, and has emerging connections to neurodegenerative diseases through its effects on neuroinflammation and prostaglandin metabolism.
Structure and Mechanism
Protein Structure
SLCO2A1 is a 643-amino acid transmembrane transporter belonging to the SLCO (Solute Carrier Organic Anion) family. The protein contains 12 transmembrane domains that form the transport pore, with extracellular and intracellular loops involved in substrate recognition and binding.
Transport Mechanism
SLCO2A1 operates as a proton-coupled symporter:
Utilizes the proton gradient as an energy source
Transports organic anions in exchange for protons
Exhibits broad substrate specificity for prostaglandins and related molecules
Function
Prostaglandin Transport
SLCO2A1 is the primary transporter for:
Prostaglandin E2 (PGE2)
Prostaglandin F2α (PGF2α)
Prostaglandin D2 (PGD2)
Prostaglandin I2 (PGI2/Prostacyclin)
Leukotriene C4 and E4
Tissue Distribution
High expression in:
Platelet-derived microvascular endothelial cells
Lung, kidney, and liver
Brain (particularly in endothelial cells of the blood-brain barrier)
Spinal cord
Role in Inflammation
By mediating prostaglandin uptake, SLCO2A1 regulates:
Inflammatory responses
Vasodilation
Platelet aggregation
Pain perception
Disease Associations
Alzheimer's Disease
SLCO2A1 has emerging connections to AD through neuroinflammation:
Prostaglandin Dysregulation: Altered prostaglandin transport in AD brains may contribute to chronic neuroinflammation. PGE2, when elevated chronically, promotes glial activation and neuronal dysfunction.
[Blood-Brain Barrier](/entities/blood-brain-barrier) Function: As expressed in brain endothelial cells, SLCO2A1 may influence prostaglandin flux across the BBB, affecting neuroinflammatory processes.
Genetic Associations: Certain SLCO2A1 variants have been nominally associated with AD risk in genome-wide studies, though replication is needed.
Primary Hypertrophic Osteoarthropathy
Biallelic SLCO2A1 mutations cause primary hypertrophic osteoarthropathy (PHO), characterized by:
Digital clubbing
Periostitis
Arthropathy
Cutaneous changes
This highlights SLCO2A1's essential role in prostaglandin metabolism, as PHO results from impaired prostaglandin clearance.
Other Inflammatory Conditions
SLCO2A1 variants have been associated with:
Inflammatory bowel disease
Asthma
Rheumatoid arthritis
Therapeutic Implications
Drug Transport
SLCO2A1 transports various drugs and compounds:
Antibiotics (e.g., cefotaxime)
Antihistamines
Statins
Chemotherapeutic agents
Understanding SLCO2A1 function is important for drug delivery to the brain and inflammatory tissues.
Targeting Strategies
Small molecule modulators of SLCO2A1 transport activity